Core Insights - Renovaro Inc. is expanding its strategic collaboration with Nebul to enhance early detection of cancer and other diseases through AI-driven precision medicine [1][2] - The partnership will utilize Renovaro's deep learning and machine learning programs alongside Nebul's high-performance computing capabilities to accelerate biomarker discovery and diagnostics [1][2] Company Overview - Renovaro Inc. focuses on precision and personalized medicine, leveraging AI and biotechnology for early diagnosis, targeted treatments, and drug discovery [4] - The company includes divisions such as RenovaroBio, which specializes in cell-gene immunotherapy, and RenovaroCube, which utilizes AI for multi-omic diagnostics and drug development [4] Partnership Details - The collaboration with Nebul aims to develop an improved diagnostic test for lung cancer that can detect minimal residual disease (MRD), which is crucial for preventing patient relapse [2] - Nebul's data centers will provide the necessary high-performance computing power, secure infrastructure, and scalability for Renovaro's deep learning AI models [2] Nebul Overview - Nebul offers a European private AI cloud that combines enterprise-class capabilities with the scalability of global hyper-scalers, ensuring secure processing of healthcare data [3] - The company has achieved certifications such as NEN 7510 and ISO 27001, demonstrating compliance with stringent standards for data security in healthcare applications [3]
Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs